A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion

Malignant ascites and pleural effusion are challenging clinical problems, with a major impact on quality of life. We conducted a randomized phase II trial to assess the palliative value of cediranib, an oral vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI). After a baseline pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2014-12, Vol.9 (4), p.331-338
Hauptverfasser:	Mulder, S. F., Boers-Sonderen, M. J., van der Heijden, H. F. M., Vissers, K. C. P., Punt, C. J. A., van Herpen, C. M. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Administration, Oral Aged Antineoplastic Agents - administration & dosage Ascites - drug therapy Biological and medical sciences Biomedicine Disease Progression Drug Administration Schedule Female Gastroenterology. Liver. Pancreas. Abdomen Humans Male Medical sciences Medicine Medicine & Public Health Middle Aged Oncology Original Research Other diseases. Semiology Palliative Care - methods Paracentesis Pleural Effusion - drug therapy Pneumology Protein Kinase Inhibitors - administration & dosage Quality of Life Quinazolines - administration & dosage Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Time Factors Treatment Outcome Tumors of the respiratory system and mediastinum Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!